FCMI
Foresite Capital Management IV Portfolio holdings
AUM
$124M
This Quarter Return
+42.75%
1 Year Return
-24.36%
3 Year Return
+1.86%
5 Year Return
+16.17%
10 Year Return
–
AUM
$198M
AUM Growth
+$198M
(+9.9%)
Cap. Flow
-$38.5M
Cap. Flow
% of AUM
-19.45%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
1
Reduced
1
Closed
2
Top Buys
| 1 |
Pharvaris
PHVS
|
$8.29M |
Top Sells
| 1 |
CBAY
Cymabay Therapeutics
CBAY
|
$26.6M |
| 2 |
Aclaris Therapeutics
ACRS
|
$19.2M |
| 3 |
Lyell Immunopharma
LYEL
|
$892K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Pharvaris
PHVS
$1.41B
| $113M | 57.25% |
4,038,842
+295,392
| +8% | +$8.29M |
|
2
Kura Oncology
KURA
$732M
| $26.6M | 13.44% |
1,849,947
| – | – |
|
|
KNTE
3
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $22.9M | 11.58% |
9,671,643
| – | – |
|
4
Syndax Pharmaceuticals
SNDX
$1.39B
| $18.9M | 9.56% |
875,000
| – | – |
|
|
5
Lyell Immunopharma
LYEL
$220M
| $16.2M | 8.16% |
8,325,000
-459,813
| -5% | -$892K |
|
|
CBAY
6
DELISTED
Cymabay Therapeutics
CBAY
| – | – |
-1,787,094
| Closed | -$26.6M |
|
|
7
Aclaris Therapeutics
ACRS
$223M
| – | – |
-2,808,034
| Closed | -$19.2M |
|